Proactive Psycho-Social Support May Improve Mental Health in Oncology Care
Kelly Dyckman, MSW, LCSW, discusses the need for proactive, not reactive, communication about post-treatment challenges to better support cancer survivors.
Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence
Oncotype DX 21-gene recurrence scores may help select certain patients who are suitable to omit radiotherapy for early-stage breast cancer.
Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer
Cryoablation, when combined with adjuvant endocrine therapy, may offer a minimally invasive outpatient strategy in older patients with breast cancer.
Giving Psychosocial Support for Sexual Health Issues in Cancer Care
Recommending counseling sessions may help patients with cancer navigate sexual health and emotional issues during their cancer treatment.
Uveal Melanoma Study Shows High Efficacy Rates After RT/Vitrectomy Regimen
Tara A. McCannel, MD, PhD, discusses how brachytherapy plaque with vitrectomy and silicone oil led to a 100% survival rate in patients with uveal melanoma.
The Essential Role of Clinical Social Work in Oncology
Kelly Dyckman, MSW, LCSW, discusses how her role integrates with multidisciplinary oncology teams to support patients' emotional and relational well-being.
FDA Grants Priority Review to BLA for Orca-T in Hematologic Malignancies
The regulatory agency gave a PDUFA target action date of April 6. 2026 for Orca-T among patients with AML, ALL, and MDS.
Antiemetic Regimen Limits Chemo-Induced Nausea/Vomiting in Multiple Myeloma
Patients with multiple myeloma who received palonosetron, dexamethasone, aprepitant, and olanzapine achieved a 44.1% CR rate across all study phases.
Intravesical Mitomycin Produces Enduring Efficacy Across NMIBC Trials
Data support the intravesical mitomycin solution’s role as an innovative option for those with recurrent, low-grade, intermediate-risk NMIBC.
Dato-DXd Improves Survival in Recurrent Inoperable/Metastatic TNBC
The safety profile of dato-DXd was consistent with previous clinical trials assessing the agent in breast cancer.
Casdatifan Monotherapy Achieves Clinical Activity in Late-Line Kidney Cancer
Casdatifan, administered at 100 mg once daily, achieved a confirmed ORR of 35% in patients with pretreated metastatic kidney cancer.
Who Should Receive RT Plus Vitrectomy/Silicone Oil in Uveal Melanoma?
Patients with uveal melanoma who have tumors larger than 2 mm are candidates for brachytherapy plaque with vitrectomy and silicone oil.
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors
A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
How Will RLTs Be Integrated Into the Prostate Cancer Treatment Paradigm?
Evaluating RLT-based combinations, RLTs across genitourinary cancers, and in earlier lines of therapy are among the considerations for further research.
Prognosis Strategy Exhibits Similar Transplant Outcomes in Select Patients
A study by the Blood and Marrow Transplant Clinical Trials Network found that a donor search prognosis strategy may move those with cancer to HCT faster.
What Direction Should Marginal Zone Lymphoma Research Be Heading?
Tara M. Graff, DO, MS, stated that combination therapy approaches may be the optimal route forward for advancing MZL care.
Two-Fraction SBRT Shows Acceptable Toxicity in Prostate Cancer Population
Grade 2 or higher genitourinary acute toxicity was observed in 27.3% of patients treated with 2 fractions of SBRT vs 29.2% of patients treated with 5.
Progastrin-Releasing Peptide Levels Correlate With OS and PFS in LS-SCLC
Those with limited-stage small cell lung cancer who had elevated ProGRP levels at baseline had worse OS and PFS outcomes vs those with normalized levels.
How Does SC Mosunetuzumab Compare With Other Frontline MZL Therapies?
“…if [there’s] a younger patient with MZL, I’m willing to risk a little extra toxicity to give them a longer-term remission,” said Tara M. Graff, DO, MS.
Unraveling The Benefits of Twice-Daily Chemoradiotherapy in LS-SCLC
Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.
Looking Beyond Genomics to Advance Precision Medicine in Cancer Care
Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.
Is SC Mosunetuzumab an Effective and Safe Frontline MZL Therapy?
Subcutaneous mosunetuzumab achieved consistent rates of complete responses across various high-risk marginal zone lymphoma subgroups.
Sunvozertinib Exhibits Favorable Responses in EGFR-Mutated NSCLC
Treatment-related AEs with sunvozertinib were consistent with EGFR tyrosine kinase inhibitors in patients with NSCLC with EGFR exon 20 insertion mutations.
Exploring the Next Frontier of Cancer Biomarkers in Precision Medicine
Beyond DNA-centric diagnostics, protein-based methods may play a role in accurately matching patients with the most effective therapies.
Uncovering Subsequent Research Considerations for Tarlatamab in ES-SCLC
Biomarker research is needed to better ascertain patient benefit with tarlatamab among those with relapsed extensive-stage small cell lung cancer.
Monitoring Response to Radioligand Therapy in Prostate Cancer
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
How Will Indolent Lymphoma/B-Cell NHL Care Be Improved in the Future?
There will be an unmet need for therapy in patients with aggressive lymphomas who did not benefit from therapy with bispecifics, CAR-T, chemotherapy, and targeted therapy.
FDA Approves Lurbinectedin/Atezolizumab Maintenance in ES-SCLC
Data from the phase 3 IMforte trial support the FDA approval of maintenance lurbinectedin plus atezolizumab in extensive-stage small cell lung cancer.
How to Optimize Quality of Life During Thoracic Radiotherapy for LS-SCLC?
Less lymphocyte depletion with twice-daily radiotherapy warrants further assessment to optimize the synergistic effect of radiotherapy and immunotherapy.